Photo of Camelia Iancu-Rubin

Camelia Iancu-Rubin

  • ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
Print ProfilePrint Profile


  • M.S., University of Medicine and Pharmacy

  • Ph.D., University of Bucharest

  • Mount Sinai School of Medicine


  • 2010 - 2011
    The Tisch Cancer Institute Development Award
    Mount Sinai School of Medicine

  • 2007 - 2012
    Mentored Scientist Career Development Award

  • 1997 - 1999
    Fulbright Felowship in Biomedical Sciences
    IIE/CUNY Mount Sinai Graduate School of Biomedical Sciences


Research Interests

Megakaryopoiesis is a complex process in which bone marrow progenitors proliferate and acquire megakaryocyte-specific markers in the early stages, then undergo polyplodization (i.e. multiple rounds of DNA replication in the absence of cell division) and release platelets into the blood circulation in the later stages. The major goal of our research is to understand the mechanisms underlying these processes in normal and malignant megakaryopoiesis.

Dr. Iancu-Rubin is the Scientic Director of Hematological Malignancies Tissue Bank of the Tisch Cancer Institute


Atweh GF, Iancu-Rubin C. p27(Kip1) and STMN1: partners again?. Cell cycle (Georgetown, Tex.) 2014; 13(20).

Iancu-Rubin C, Mosoyan G, Glenn K, Gordon RE, Nichols GL, Hoffman R. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Experimental hematology 2014 Feb; 42(2).

Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap.. Exp Hematol 2013; 41(2): 155-166.

Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas JE, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.. Exp Hematol 2012 July; 40(7): 564-574.

Iancu-Rubin C, Gajzer D, Tripodi J, Gordon R, Hoffman R, Atweh GF. Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood 2011 Apr; 17(17).

Chen J, Peterson KF, Iancu-Rubin C, Bieker JJ. Design of embedded chimeric peptide nucleic acids that efficiently enter and accurately reactivate gene expression in vivo. Proceedings of the National Academy of Sciences of the United States of America 2010 Sep; 107(39).

Iancu-Rubin C, Atweh GF. p27(Kip1) and stathmin share the stage for the first time.. Trends in cell biology 2005 Jul; 15(7).

Iancu-Rubin C, Nasrallah CA, Atweh GF. Stathmin prevents the transition from a normal to an endomitotic cell cycle during megakaryocytic differentiation. Cell cycle 2005 Dec; 93(12).

Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J of Cell Sci 2004 Oct; 93(2).

Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of Stathmin Inhibition on the Mitotic Spindle. J of Cell Sci 2001; 114(5): 3537-3541.

Iancu C, Mistry SJ, Wallenstein I, Atweh G. Taxol and Anti-Stathmin Therapy: A Synergistic Combination that Targets the Mitotic spindle. Cancer Research 2000; 60(13): 3537-3541.

Miscalencu D, Iancu C, Mailat F, Nicolae I. Chapter I, MYC Transcription Factors. In: Transcription factors in cancer. Univ of Bucharest, Romania; 2012.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Iancu-Rubin did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building Floor 24 Room 24-45
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-8589
Fax: 212-241-4096


Annenberg Building Floor 24th Floor Room 24-45
1468 Madison Avenue
New York, NY 10029